MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Novo Nordisk A-S

Slēgts

SektorsVeselības aprūpe

62.58 2.02

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

61.34

Max

62.71

Galvenie mērījumi

By Trading Economics

Ienākumi

929M

28B

Pārdošana

14B

86B

P/E

Sektora vidējais

16.907

57.333

EPS

6.34

Dividenžu ienesīgums

2.77

Peļņas marža

32.947

Darbinieki

76,302

EBITDA

4.2B

40B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+33.8% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.77%

2.63%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

174M

285B

Iepriekšējā atvēršanas cena

60.56

Iepriekšējā slēgšanas cena

62.58

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Novo Nordisk A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. apr. 09:26 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 25. febr. 15:33 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

2025. g. 5. febr. 11:53 UTC

Peļņas

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

2025. g. 22. apr. 09:31 UTC

Karstas akcijas

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

2025. g. 11. apr. 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Novo Remade Denmark. Then Came the Stock Selloff. -2-

2025. g. 11. apr. 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

2025. g. 10. apr. 05:00 UTC

Peļņas

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

2025. g. 2. apr. 11:25 UTC

Tirgus saruna

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2025. g. 2. apr. 09:27 UTC

Karstas akcijas

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

2025. g. 31. marts 12:49 UTC

Tirgus saruna

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

2025. g. 28. marts 15:11 UTC

Tirgus saruna

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

2025. g. 27. marts 13:45 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

2025. g. 24. marts 10:19 UTC

Tirgus saruna

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

2025. g. 24. marts 09:08 UTC

Tirgus saruna
Peļņas

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

2025. g. 19. marts 15:54 UTC

Top Ziņas

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025. g. 11. marts 15:31 UTC

Tirgus saruna

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

2025. g. 11. marts 14:58 UTC

Tirgus saruna

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 10. febr. 12:00 UTC

Top Ziņas

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025. g. 7. febr. 10:30 UTC

Top Ziņas

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025. g. 6. febr. 16:16 UTC

Top Ziņas
Peļņas

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025. g. 6. febr. 14:56 UTC

Peļņas

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025. g. 5. febr. 13:59 UTC

Peļņas

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

2025. g. 5. febr. 12:02 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

2025. g. 5. febr. 11:35 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

2025. g. 5. febr. 10:10 UTC

Karstas akcijas

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

2025. g. 5. febr. 09:43 UTC

Peļņas

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

2025. g. 5. febr. 08:47 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

2025. g. 5. febr. 08:38 UTC

Tirgus saruna
Peļņas

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S Prognoze

Cenas mērķis

By TipRanks

33.8% augšup

Prognoze 12 mēnešiem

Vidējais 83.8 USD  33.8%

Augstākais 105 USD

Zemākais 61 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

2

Pirkt

5

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

62.4 / 64.49Atbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.